Semaglutide and Tirzepatide in 2025: End of Shortages and What It Means

Shortage Timeline & Current Status

The journey of GLP-1 medication shortages has been a defining challenge for patients and healthcare providers. Understanding the timeline helps contextualize the current situation and what to expect moving forward.

Historical Shortage Timeline

Current Availability by Medication

Learn more about how to access semaglutide and tirzepatide options in the current market.

Supply Chain Analysis: What Caused the Shortages

The GLP-1 medication shortages that began in 2022 were driven by a convergence of factors that collectively overwhelmed the pharmaceutical supply chain. Understanding these root causes is important both for contextualizing the current resolution and for assessing the likelihood of future supply disruptions.

Unprecedented demand growth was the primary driver. When semaglutide and tirzepatide demonstrated weight loss results far exceeding any previous pharmaceutical intervention, prescriptions surged at a pace that no manufacturer could have anticipated during initial production planning. The medications went from niche diabetes treatments to mainstream weight management therapies almost overnight, fueled in part by social media attention and celebrity endorsements. Novo Nordisk and Eli Lilly had built manufacturing capacity based on projected diabetes patient volumes, not the tens of millions of potential weight loss patients who suddenly sought prescriptions.

Manufacturing complexity compounded the problem. Both semaglutide and tirzepatide are peptide-based medications produced through sophisticated biological manufacturing processes that cannot be scaled up as quickly as traditional small-molecule drugs. Building a new peptide manufacturing facility requires three to five years from planning to production, and expanding existing facilities involves rigorous FDA validation processes. The active pharmaceutical ingredients require precise fermentation, purification, and formulation steps that limit throughput and make rapid production increases extremely challenging.

Global supply chain constraints also played a role. The specialized glass vials, autoinjector components, and fill-finish capacity needed for injectable medications were already under strain from lingering pandemic-era disruptions. Competition for these shared resources among multiple pharmaceutical products further limited manufacturers' ability to ramp up GLP-1 production.

FDA Actions & Manufacturer Updates

The FDA's decision to remove tirzepatide from the shortage list reflects significant improvements in manufacturing capacity and supply chain management.

Manufacturer Production Increases

FDA Regulatory Updates

The FDA has taken several regulatory actions throughout the shortage period that directly impact patient access. The agency's decision to formally end the tirzepatide shortage listing in October 2024 was based on confirmed production capacity meeting projected demand. For semaglutide, the FDA has maintained its shortage listing while acknowledging substantial supply improvements, with a full resolution expected in the near term. These regulatory determinations carry significant legal and practical implications, particularly for compounding pharmacies. Under federal law, compounding pharmacies may produce copies of commercially available drugs only when those drugs appear on the FDA shortage list. Once a medication is removed from the list, compounding pharmacies generally must cease production of that specific drug, though the timeline and enforcement of this transition has been subject to legal challenges.

Compounded Medication Access

The changing shortage status has significant implications for patients currently using compounded versions of these medications.

For more information on compounded options, read our guide on compounded semaglutide safety and cost comparisons.

Switching Strategies: Compounded to Brand-Name

Patients currently using compounded semaglutide or tirzepatide face the practical challenge of transitioning to brand-name products as shortage resolutions restrict compounding access. This transition requires careful planning to maintain treatment continuity and avoid disruption to weight loss progress.

The first consideration is dose equivalence. Compounded medications may be formulated at different concentrations or dose increments than the commercially available products. Patients and providers should carefully map the compounded dose to the nearest available brand-name dose strength. In most cases, transitioning to the same milligram dose is straightforward, but differences in formulation may occasionally result in slightly different absorption profiles, which could temporarily affect side effects or efficacy. Providers should schedule a follow-up within two to four weeks after switching to assess tolerance and adjust dosing if needed.

Timing the switch requires coordination between the compounding pharmacy, the new dispensing pharmacy, and insurance authorization processes. Patients should initiate the transition at least four to six weeks before their compounded supply runs out, as insurance prior authorization for brand-name GLP-1 medications can take two to four weeks. Working with your provider's office to submit prior authorization paperwork early is essential to avoid gaps in treatment. Some patients may benefit from obtaining a bridge supply of compounded medication to cover the authorization period.

For patients who cannot afford the transition to brand-name pricing, several options exist. Manufacturer savings programs from both Novo Nordisk and Eli Lilly can reduce out-of-pocket costs substantially for commercially insured patients. Patient assistance programs serve uninsured or underinsured individuals who meet income requirements. Some healthcare providers also explore switching between medications, for example transitioning a patient from compounded tirzepatide to brand-name semaglutide if the latter is available at lower cost through their insurance plan. While switching between GLP-1 medications is not a direct substitute, many patients successfully transition between these agents with appropriate dose mapping and monitoring.

What Patients Should Do Now

If you're currently taking or considering GLP-1 medications, here's your action plan for navigating the changing landscape.

The Bottom Line

The resolution of GLP-1 medication shortages marks a significant milestone in weight management treatment. While the end of shortages brings challenges—particularly around cost and access to compounded medications—it also ensures better medication quality, consistency, and long-term availability.

Stay informed about the latest developments in GLP-1 medications by reading our Complete GLP-1 Guide and comparing your options with Tirzepatide vs Semaglutide.